Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 8/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | HTR1A | P08908 | 11/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24697655 | 0.84 | SLC6A2 (0.46) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL31535455 | 0.81 | SLC6A2 (0.44) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL16334980 | 0.81 | SLC6A2 (0.44) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL31535524 | 0.81 | SLC6A2 (0.41) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL25937248 | 0.78 | SLC6A2 (0.40) | GRIN1GRIN2BSLC6A2HTR1ASLC6A3 | |
| SCHEMBL31535200 | 0.77 | EPHX2 (0.34) | SLC6A2HTR1ASLC6A3 | |
| SCHEMBL31535343 | 0.76 | SLC6A2 (0.40) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL4491466 | 0.74 | SMN1; SMN2 (0.40) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL589662 | 0.67 | KRAS (0.39) | — | |
| SCHEMBL1423462 | 0.67 | DHFR (0.34) | SLC6A2HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | GRIN1 699/4885GRIN2B 848/4885SLC6A2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.